Loading…
← CockpitCompetitor Analysis › 301370.SZ GKHT Medical Technology Co., Ltd. Class AOpen in the cockpit ↗

GKHT Medical Technology Co., Ltd. Class A301370.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Distributors
Momentum neutral 50
Mkt cap
$525M
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$2.94M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-3.9 pp
WACC 6.3%
Hurdle
+6 pp
Req g minus delivered
Close · CNYCN¥7.62
1D-2.2%
1W-6.2%
1M-9.5%
3M-17.1%
6M-24.2%
YTD-34.8%
1Y-30.3%
ATR %2.7%
52w lowhigh42.0% off high

What GKHT Medical Technology does

Employees: 873

GKHT Medical Technology at a glance

Size GKHT Medical Technology (301370.SZ) is a China Health Care company (Medical Distributors) with a market value of $525M, the 3581st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.62 on 18 Nov 2026.

Performance Over six months the shares fell 24.2%, against -2.3% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 10.7% over the last twelve months (peer median +3.9%); the operating margin is 0.6% (peer median 2.3%).

Valuation It trades at 0.7× enterprise value to sales against a peer median of 1.2× (8th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.9 points below its cost of capital (6.3% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 97301370.SZ 78
Six months, rebased to 100: GKHT Medical Technology against the median of its 20 peers (local-currency closes).

GKHT Medical Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.43BCN¥6.96BCN¥7.33BCN¥7.46BCN¥6.34B
Revenue growth—-5%-2%+18%—
Gross profitCN¥644MCN¥628MCN¥669MCN¥759MCN¥720M
EBITDAn/aCN¥212MCN¥350MCN¥429MCN¥415M
Net incomeCN¥11.7MCN¥68.2MCN¥131MCN¥154MCN¥125M
Free cash flowCN¥422MCN¥646MCN¥606MCN¥562MCN¥214M
Capital expenditureCN¥155MCN¥32.3MCN¥42.8MCN¥155MCN¥267M
Total debtCN¥1.67BCN¥1.32BCN¥1.49BCN¥1.48BCN¥2.78B

Quarterly statements and history in the cockpit →

GKHT Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%6006282733605136603716661700007841043151301166688366ENTERO000668ARJO-B603368301584DOCM7476301370.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. GKHT Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×2×4×6006282733605136603716661700007841043151NEU3011667447688366ENTERO000668ARJO-B603368301584301370.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GKHT Medical Technology is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%600628273360513600007831517447688366ENTERO000668603368301584301370.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. GKHT Medical Technology is the large dot.

GKHT Medical Technology competitors and peer comparison

How GKHT Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GKHT Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure301370.SZPeer medianRank in peer set
1-month return-9.5%-3.7%5th lowest of 21
6-month return-24.2%-2.3%6th lowest of 21
Distance from 52-week high-42.0%-20.5%7th lowest of 21
Revenue growth (TTM)-10.7%+3.9%3rd lowest of 21
Operating margin0.6%2.3%8th lowest of 21
EV / Sales0.7×1.2×8th cheapest of 21
Growth the price implies (Req g, 7 yrs)13.1%0.0%5th most demanding of 16
Growth delivered (Del g)+7.5%+5.7%6th highest of 16
Hurdle (Req g minus delivered)+5.6 pp-5.3 pp3rd most demanding of 16
ROIC minus cost of capital-3.9 pp-0.2 pp8th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%0.7×13.1%+7.5%
Shanghai New World 600628.SSChina$573M-10%-2%6%2.1×-1.6%+1.0%
Arata 2733.TJapan$576M-3%+3%1%0.1×-6.2%+3.8%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%1.1×21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%4.3×n/an/a
Gongwin Biopharm 6617.TWOTaiwan$412M+87%+12%-530%288.8×n/an/a
Shenzhen Neptunus Bioengineering 000078.SZChina$411M-48%-22%-1%0.6×58.3%-7.8%
Excelsior Medical 4104.TWTaiwan$404M+5%+11%8%1.4×-1.2%+5.7%
Vital KSK 3151.TJapan$399M-1%+3%0%0.1×4.7%+2.6%
Neuca NEU.WAPoland$795M-9%+8%2%0.3×5.3%+8.1%
Shanghai Universal Biotech 301166.SZChina$337M-15%+15%-4%1.0×n/an/a
Nagaileben 7447.TJapan$319M0%+1%21%1.6×-12.7%-0.4%
Shanghai Haohai Biological Technology 688366.SSChina$878M-24%-9%-2%1.8×16.9%+13.2%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%1.2×24.7%+29.9%
Rongfeng 000668.SZChina$297M-32%+61%14%4.8×9.6%+30.0%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%

Questions

Which companies are GKHT Medical Technology's closest peers?
The cockpit's peer set: Shanghai New World (600628.SS), Arata (2733.T), Shanghai Lily & Beauty Cosmetics (605136.SS), Thalys Medical Technology (603716.SS), Gongwin Biopharm (6617.TWO), Shenzhen Neptunus Bioengineering (000078.SZ), Excelsior Medical (4104.TW), Vital KSK (3151.T).
Is GKHT Medical Technology expensive compared with its peers?
On ev / sales it trades at 0.7× against a peer median of 1.2×, 8th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has GKHT Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -24.2% against -2.3% for the median peer; over one year -30.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.